Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Rell L. Parker"'
Autor:
Christina Vezza DVM, Lauren Ruger PhD, Maya Langman MD, Elliana Vickers, Francesco Prada MD, Jonathan Sukovich PhD, Timothy Hall PhD, Zhen Xu PhD, Rell L. Parker DVM, PhD, Eli Vlaisavljevich PhD, John H. Rossmeisl DVM
Publikováno v:
Technology in Cancer Research & Treatment, Vol 23 (2024)
Objective Brain tumors represent some of the most treatment refractory cancers, and there is a clinical need for additional treatments for these tumors. Domesticated dogs are the only other mammalian species which commonly develop spontaneous brain t
Externí odkaz:
https://doaj.org/article/ce92bba20dbd42b7b8b3c40df381d928
Publikováno v:
Journal of Veterinary Internal Medicine, Vol 38, Iss 3, Pp 1577-1582 (2024)
Abstract Background Neurofilament light chain (NfL) is a frequently used biomarker in humans for both diagnostic and therapeutic monitoring purposes in various neurologic diseases. Hypothesis/Objectives It was hypothesized that dogs with diagnosed st
Externí odkaz:
https://doaj.org/article/b0b779c317984f0b86b6795d08865e77
Autor:
Richard L. Shinn, Christopher Hollingsworth, Rell L. Parker, John H. Rossmeisl, Stephen R. Werre
Publikováno v:
Frontiers in Veterinary Science, Vol 11 (2024)
The objective of this research was to compare two previously described stereotactic brain biopsy (SBB) techniques, three-dimensional skull contoured guides (3D-SCGs) and neuronavigation with Brainsight, to a novel SBB technique using Brainsight combi
Externí odkaz:
https://doaj.org/article/f4719ab4fdf04d2187a4006bc8fd18a1
Publikováno v:
Journal of Veterinary Internal Medicine, Vol 37, Iss 4, Pp 1447-1454 (2023)
Abstract Background In humans, the T2‐weighted (T2W)—fluid‐attenuated inversion recovery (FLAIR) mismatch sign (T2FMM) is a specific imaging biomarker for the isocitrate dehydrogenase 1 (IDH1)‐mutated, 1p/19q non‐codeleted low‐grade astro
Externí odkaz:
https://doaj.org/article/c9bc1abdcd164c77ae245023e4afc05b
Autor:
Rell L. Parker, John Du, Richard L. Shinn, Adam G. Drury, Fang‐Chi Hsu, John L. Roberston, Thomas E. Cecere, Avril U. Arendse, John H. Rossmeisl
Publikováno v:
Journal of Veterinary Internal Medicine, Vol 36, Iss 2, Pp 694-701 (2022)
Abstract Background Seizures in the early postoperative period after intracranial surgery may affect outcome in dogs. Objectives To determine the incidence of early postoperative seizures (EPS) in dogs with brain tumors, identify specific risk factor
Externí odkaz:
https://doaj.org/article/48077e4db00b4eacb66886a7a2490099
Autor:
Kayla M. Fowler, Timothy A. Bolton, John H. Rossmeisl, Avril U. Arendse, Karen M. Vernau, Ronald H. L. Li, Rell L. Parker
Publikováno v:
Frontiers in Veterinary Science, Vol 9 (2022)
Three juvenile dogs presented with an acute onset of paraspinal hyperesthesia and/or neurologic deficits. These dogs underwent anesthesia for MRI and additional diagnostics. The thoracolumbar MRI in Dog 1 revealed an accumulation of T2-weighted (T2W)
Externí odkaz:
https://doaj.org/article/22356ddc4dad481196b735ed22664baf
Autor:
Vishal D. Murthy, Ehren McLarty, Kevin D. Woolard, Rell L. Parker, Gregg Kortz, Jamie N. King, Robert H. Poppenga, Marguerite F. Knipe, Peter J. Dickinson
Publikováno v:
Frontiers in Veterinary Science, Vol 9 (2022)
Bromethalin toxicosis is an increasingly common clinical presentation in dogs that may be fatal depending on the extent of intoxication. Antemortem diagnosis of bromethalin toxicosis was achieved in three dogs by demonstration of the active metabolit
Externí odkaz:
https://doaj.org/article/15edbfce93f247ce9a44cabf9c702fde
Autor:
Rell L Parker, Heidi C O'Neill, Beverley M Henley, Charles R Wageman, Ryan M Drenan, Michael J Marks, Julie M Miwa, Sharon R Grady, Henry A Lester
Publikováno v:
PLoS ONE, Vol 12, Iss 12, p e0188715 (2017)
The α6 nicotinic acetylcholine receptor (nAChR) subunit is an attractive drug target for treating nicotine addiction because it is present at limited sites in the brain including the reward pathway. Lynx1 modulates several nAChR subtypes; lynx1-nACh
Externí odkaz:
https://doaj.org/article/2f56db3f51614a81b5acf01883f73afa
Autor:
Julie M. Miwa, Ryan M. Drenan, Rell L. Parker, Michael J. Marks, Beverley M. Henley, Charles R. Wageman, Sharon R. Grady, Henry A. Lester, Heidi C. O'Neill
Publikováno v:
PLoS ONE
PLoS ONE, Vol 12, Iss 12, p e0188715 (2017)
PLoS ONE, Vol 12, Iss 12, p e0188715 (2017)
The α6 nicotinic acetylcholine receptor (nAChR) subunit is an attractive drug target for treating nicotine addiction because it is present at limited sites in the brain including the reward pathway. Lynx1 modulates several nAChR subtypes; lynx1-nACh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f19659dfc8d0928faafc81c9ea8553f9
https://resolver.caltech.edu/CaltechAUTHORS:20171211-155148787
https://resolver.caltech.edu/CaltechAUTHORS:20171211-155148787
Autor:
Rell L. Parker, Caroline Y. Yu, Henry A. Lester, Christopher I. Richards, Julie M. Miwa, Brandon J. Henderson, Weston A. Nichols
Glycosylphosphatidylinositol-anchored neurotoxin-like receptor binding proteins, such as lynx modulators, are topologically positioned to exert pharmacological effects by binding to the extracellular portion of nAChRs. These actions are generally tho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebae799357175153cc3892ae55458681
https://resolver.caltech.edu/CaltechAUTHORS:20140915-092705574
https://resolver.caltech.edu/CaltechAUTHORS:20140915-092705574